Details of the Drug Reposition

General Information of This Drug (ID: DMSI5CB)

• Drug Name: Chloroquine (DMSI5CB)
• Synonyms: Amokin; Aralen; Aralen HCl; Arechin; Arechine; Arequin; Arolen; Arthrochin; Artrichin; Avlochlor; Avloclor; Bemaco; Bemaphate; Bemasulph; Benaquin; Bipiquin; CU-01000012392-2; Capquin; Chemochin; Chingamin; Chloraquine; Chlorochin; Chlorochine; Chlorochinum; Chloroin; Chloroquin; Chloroquina; Chloroquine (USP/INN); Chloroquine (VAN); Chloroquine Bis-Phosphoric Acid; Chloroquine FNA (TN); Chloroquine [USAN:INN:BAN]; Chloroquine phosphate; Chloroquinium; Chloroquinum; Chloroquinum [INN-Latin]; Chlorquin; Cidanchin; Clorochina; Clorochina [DCIT]; Cloroquina; Cloroquina [INN-Spanish]; Cocartrit; Dawaquin (TN); Delagil; Dichinalex; Elestol; Gontochin; Gontochin phosphate; Heliopar; Imagon; Ipsen 225; Iroquine; Khingamin; Klorokin; Lapaquin; Malaquin; Malaquin (*Diphosphate*); Malaren; Malarex; Mesylith; Miniquine; Neochin; Nivachine; Nivaquine B; Pfizerquine; Quinachlor; Quinagamin; Quinagamine; Quinercyl; Quingamine; Quinilon; Quinoscan; RP 3377; RP-3377; Resochen; Resochin; Resochin (TN); Resoquina; Resoquine; Reumachlor; Reumaquin; Rivoquine; Ro 01-6014/N2; Ronaquine; Roquine; SN 6718; SN-7618; ST 21; ST 21 (pharmaceutical); Sanoquin; Silbesan;Siragan; Solprina; Sopaquin; Tanakan; Tanakene; Tresochin; Trochin; W 7618;WIN 244
• Therapeutic Class: Antimalarials
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

4 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Plasmodium ovale malaria	DISI8EFB	N.A.	Approved	[1]
Plasmodium malariae malaria	DIS2XHCT	N.A.	Approved	[1]
Plasmodium falciparum malaria	DIS3Q9KF	1F40	Approved	[1]
Systemic lupus erythematosus	DISI1SZ7	4A40.0	Approved	[1]

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Coronavirus Disease 2019 (COVID-19)	DISM7GNX	1D6Y	Phase 3	[2]

1 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Rheumatoid arthritis	DISTSB4J	FA20	Discontinued in Phase 2	[3]

2 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Middle East Respiratory Syndrome (MERS)	DIS5VPYU	1D64	Investigative	[4]
Severe acute respiratory syndrome (SARS)	DISYW14W	1D65	Investigative	[5]

References

• [1] Chloroquine FDA Label
• [2] ClinicalTrials.gov (NCT04360759) Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19. U.S. National Institutes of Health.
• [3] Sevoflurane Sedation on Intra Cranial Pressure in Traumatic Brain Injury Patients
• [4] Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
• [5] Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.